Press Room
Press Releases 2025
Thursday, 20 February 2025 03:29
Bonus Biogroup Announces U.S. Food and Drug Administration (FDA) Clearance of an Investigational New Drug (IND) Application for MesenCure™ Phase III Clinical Study in Respiratory Distress
The Company is working to expand its indication to include patients who have respiratory distress from any cause, including acute respiratory distress syndrome (ARDS). MesenCure's market potential in all-cause ARDS in the United States alone could reach approximately $9.6 billion by 2030, according to Company estimates. TEL AVIV, Israel, February…
info@bonus-bio.com
+972 (0)73 206 7104
Matam Advanced Technology
Park P.O.B 15143 Haifa 31905 Israel
 |
 |
 |
 |
© 2022 Bonus BioGroup Ltd. Created By Netron Israel Ltd